Amicus opens UCity R&D tower, calls Philly the ‘Cradle of Cures’

A Princeton-area biotech company has moved its R&D to Philadelphia, where it will employ 200, because, its founder says, this is where the genetic scientists are. Plus, Boston is full

Amicus opens UCity R&D tower, calls Philly the ‘Cradle of Cures’

A Princeton-area biotech company has moved its R&D to Philadelphia, where it will employ 200, because, its founder says, this is where the genetic scientists are. Plus, Boston is full

The weed industry spent a record $2 million last year to lobby New Jersey. Here’s who spent that money.

Who spent big money last year to legalize marijuana in the Garden State? Here's the list.

The weed industry spent a record $2 million last year to lobby New Jersey. Here’s who spent that money.

Who spent big money last year to legalize marijuana in the Garden State? Here's the list.

‘Don’t panic,’ Philadelphia-area manufacturers say as they brace for coronavirus

Nearly 73 percent of the survey respondents believed the virus will impact their supply chains. About 14 percent said the impact would be “significant.”

‘Don’t panic,’ Philadelphia-area manufacturers say as they brace for coronavirus

Nearly 73 percent of the survey respondents believed the virus will impact their supply chains. About 14 percent said the impact would be “significant.”
More Stories
Column

Inovio stock spikes on COVID-19 coronavirus vaccine speedup

Shares of Inovio Pharmaceuticals Inc. hit a four-year high Wednesday.

Spotlight is on weed at this year’s Philadelphia Flower Show

For the first time in the history of the Philadelphia Flower Show, there will be a spotlight this year on the world’s most notorious weed.

Generic drugmakers sold most opioids during overdose crisis

Purdue Pharma has been the poster child for the U.S. opioid crisis, mostly because of aggressive marketing of its signature painkiller, OxyContin. Lesser known is the role of generic opioid manufacturers like Mallinckrodt that produced the vast majority of painkillers during the height of the overdo

Column

This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO

Philadelphia is where the future economy around gene therapy is coming together, establishing the area as an international nexus for new treatments. "Philadelphia is not going to lose this one," says one CEO.

Penn took in millions from countries like China and Saudi Arabia, and there may be more

Department of Education officials are cracking down on how schools report funds they receive from foreign sources.

Inside a Philadelphia lab, scientists race to design a coronavirus vaccine

Scientists at the Wistar Institute and its partners expect to test a vaccine in human subjects by early summer.

Why are so many people still being arrested for marijuana across Pennsylvania?

“We’re still arresting more people than we did 10 years ago,” said Lt. Gov. John Fetterman. “It’s lunacy.”

Glaxo, Merck to spin off some businesses to focus on high-profit cancer drugs and vaccines

Drug giants Glaxo and Merck, which have research, manufacturing and marketing operations in the Philadelphia area, plan to spin off slow-growing businesses to concentrate on high-profit therapies

Penn gene therapy pioneer Jim Wilson’s Passage Bio plans IPO

Penn gene therapy pioneer Jim Wilson's Passage Bio is planning to go public.

Annovis Bio is the latest Philly-area biotech firm to sell stock before it has products

Annovis is developing an anti-Alzheimer’s treatment that the company says could also be useful fighting Parkinson’s and other neurodegenerative diseases.

Delaware gets approval from USDA to grow hemp. Is that a good thing?

One industry analyst warns that aspiring hemp farmers in any state take caution.

‘Skunkworks’ at Johnson & Johnson is rushing to develop a coronavirus vaccine

J&J set up the project two weeks ago when the virus began to look like a global threat.

Pa. auditor general presses for new laws on pharmacy benefit managers

Auditor general Eugene DePasquale said Thursday said that pharmacy benefit manager business practices are “harming” independent pharmacies, and that he was concerned about the “future of competition” among retail pharmacies in the state.

Consumer
SPECIAL REPORTS
Investigative reports, featured series, and guides to living in the Philadelphia region, brought to you by The Inquirer.
WHAT ARE YOU CURIOUS 7073彩票登录?
Send us your burning questions, or vote on other readers' questions that pique your interest. Our journalists will work to answer them.